Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging

Abstract

BackgroundKidney Disease Improving Global Outcomes (KDIGO) 2013 updated the classification and risk stratification of chronic kidney disease (CKD) to include both the level of renal function and urinary albumin excretion (UAE). The update subclassifies the previous category of moderate renal impairment. There is currently limited information on the prevalence of CKD based on this new classification in United States (US) adults with type 2 diabetes mellitus (T2DM). The objective of this study was to provide such estimates, for T2DM both overall and in those ≥ 65 years of age. We used the continuous National Health and Nutrition Examination Survey (NHANES) 1999–2012 to identify participants with T2DM. Estimated glomerular filtration rate (eGFR) and UAE were calculated using laboratory results and data collected from the surveys, and categorized based on the KDIGO classification. Projections for the US T2DM population were based on NHANES sampling weights.ResultsA total of 2915 adults diagnosed with T2DM were identified from NHANES, with 1466 being age ≥ 65 years. Prevalence of CKD based on either eGFR or UAE was 43.5% in the T2DM population overall, and 61.0% in those age ≥ 65 years. The prevalence of mildly decreased renal function or worse (eGFR < 60/ml/min/1.73 m2) was 22.0% overall and 43.1% in those age ≥ 65 years. Prevalence of more severe renal impairment (eGFR < 45 ml/min/1.73 m2) was 9.0% overall and 18.6% in those age ≥ 65 years. The prevalence of elevated UAE (> 30 mg/g) was 32.2% overall and 39.1% in those age ≥ 65 years. The most common comorbidities were hypertension, retinopathy, coronary heart disease, myocardial infarction, and congestive heart failure.ConclusionsThis study confirms the high prevalence of CKD in T2DM, impacting 43.5% of this population. Additionally, this study is among the first to report US prevalence estimates of CKD based on the new KDIGO CKD staging system.

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study

“…The overall prevalence of patients with type 2 diabetes and mild renal insufficiency is estimated to be nearly 40% and prevalence increases with age (estimated to be nearly 50% in patients with type 2 diabetes ≥65 years of age) 1. Improved glycaemic control has been shown to reduce the risk of diabetic complications and to slow progression of renal impairment 10.…”

“…While the prevalence of moderate or severe renal insufficiency (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73m 2 , CKD stages 3‐5) in patients with type 2 diabetes has been estimated at approximately 22%, a larger proportion (38%) have mild renal insufficiency (eGFR ≥60 and <90 mL/min/1.73m 2 , stage 2) 1. These rates increased in those with type 2 diabetes ≥65 years of age, among whom 43% have moderate or severe renal insufficiency and 48% have mild renal insufficiency 1. While it is widely recognized that the choice of an antihyperglycaemic agent (AHA) for treatment of type 2 diabetes should be influenced by renal function, only CKD stages 3‐5 are usually considered relevant to that decision 2.…”

Metformin in advanced chronic kidney disease: are current guidelines overly restrictive?

“…Indeed, Bailey et al used National Health and Nutrition Examination Survey (NHANES) data to find a prevalence of 9% in the USA, whilst a study from Spain estimated the prevalence to be 6.4%. 25,26 Given the large burden of type 2 diabetes, these data suggest that there are a large number of diabetics with CKD who might benefit from even a mild relaxation of the eGFR cut-off for continuing metformin.…”

A Mobile-Based Question-Answering and Early Warning System for Assisting Diabetes Management

“…In subsequent medical Q&A developments, diabetes mellitus, as one of the top three major worldwide causes of death from noncommunicable diseases, has prompted numerous researches investigating the prevention, prevalence, and mortality of diabetes mellitus [15,[44][45][46][47][48][49][50][51][52][53]. There is a great demand for a Q&A system that can effectively and efficiently provide health consulting services and assist people in monitoring and managing their individual health conditions.…”